Purple Biotech Secures New US Patent for NT219 Combination Therapy
Ticker: PPBT · Form: 6-K · Filed: Mar 5, 2025 · CIK: 1614744
Sentiment: bullish
Topics: patent, intellectual-property, biotech
TL;DR
Purple Biotech just got a new US patent for NT219 combo therapy, boosting IP in major markets.
AI Summary
On March 5, 2025, Purple Biotech Ltd. announced it has been granted a new U.S. patent for its NT219 drug when used in combination with EGFR antibody therapy. This patent strengthens the company's intellectual property protection in key global markets.
Why It Matters
The new patent enhances Purple Biotech's market exclusivity for its NT219 drug, potentially increasing its commercial value and competitive advantage.
Risk Assessment
Risk Level: low — This filing is a routine announcement of a patent grant, which is generally positive news with limited immediate downside risk.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer and subject of the patent grant
- NT219 (drug) — Drug for which the patent was granted
- EGFR Antibody Therapy (therapy) — Therapy used in combination with NT219
- March 5, 2025 (date) — Date of the press release and patent grant announcement
FAQ
What is the expiration date of the newly granted U.S. patent for NT219 in combination with EGFR antibody therapy?
The filing does not specify the expiration date of the patent.
Which specific EGFR antibody therapies are covered by this new patent?
The filing does not list the specific EGFR antibody therapies covered by the patent.
What are the 'major markets' mentioned in the press release where this patent enhances IP protection?
The filing does not explicitly list the 'major markets' but implies they are key global markets.
Does this patent grant provide any new information on the clinical trial status or results for NT219?
No, this filing is solely an announcement regarding a patent grant and does not contain information on clinical trials or results.
What was Purple Biotech Ltd.'s former company name?
Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 5, 2025 regarding PURPLE BIOTECH LTD. (PPBT).